Page last updated: 2024-11-01

nialamide and Vitiligo

nialamide has been researched along with Vitiligo in 1 studies

Nialamide: An MAO inhibitor that is used as an antidepressive agent.

Vitiligo: A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.

Research Excerpts

ExcerptRelevanceReference
"Local injection of physostigmine revealed that dermatomally distributed vitiligo was associated with a dysfunction of the sympathetic nerves in the affected skin and that non-dermatomally distributed vitiligo was not."3.65Vitiligo: a new classification and therapy. ( Koga, M, 1977)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Koga, M1

Other Studies

1 other study available for nialamide and Vitiligo

ArticleYear
Vitiligo: a new classification and therapy.
    The British journal of dermatology, 1977, Volume: 97, Issue:3

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Female; Humans; Male; Middle Aged; Nialamide; Physostigm

1977